AstraZeneca and Daiichi Sankyo have moved swiftly to file for FDA approval of a second indication for their TROP2-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd), this time for ...

** THIS INFORMATION IS CORRECT AT TIME OF PUBLISHING. CHANGES MAY OCCUR WITHOUT PRIOR NOTICE. THE CINEMAS RESERVE THE RIGHT TO CANCEL ANY SHOW 30 – 60 MINUTES BEFORE THE SHOW STARTS. CHANGES SUCH AS ...